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After more than a decade, combined multimodality imaging
has now become a clinical reality. The combination of SPECT
and CT has transformed the plain and simple bone scan into a
quantitative imaging procedure. Coming from the undervalued
“spots and dots” corner, the combination of functional und
anatomical imaging has led to an increased acceptance among
the imaging community as well as among referring physicians.
The other prominent multimodality combination of this decade
is that of PET and CT (called PET/CT). Being considered a
quantitative combination right from the beginning, it has been
used mainly in oncology imaging for staging, restaging, ther-
apy follow-up and prognostic stratification. PET/CT has been
shown to increase the average diagnostic accuracy by up to
15 % [1]. It helps avoid biopsies and leads to changes in
therapy planning in almost all solid tumour entities [2].
Both SPECT/CT and PET/CT have their distinctive posi-
tion within the clinical and academic environment, and have
forced radiologists and nuclear medicine physicians to change
their working philosophies and to think in terms of hybrid
imaging rather than staying with their traditional in-house
modalities alone. This evolution may be even more accelerat-
ed with the advent of PET/MRI. It is widely accepted now that
fusing the advantages of both radiology and nuclear medicine
(or molecular imaging), be it through joined reporting by two
specialists or through obtaining dual board certification, leads
to a better diagnosis and thus ultimately to a benefit for the
patient.
The development of the SPECT/CT concept was primarily
driven by academia. A prototype for human use was presented
as early as in the 1990s [3]. The concept then encouraged
further commercial development and the first industry-built
systems became available on the market in the late 1990s [4].
Today, several SPECT/CT design concepts are available com-
mercially, and more so for preclinical use. Advanced system
configurations including SPECT systems combined with CT
ranging from lower-end to multislice CT systems, including
iterative image reconstruction and advanced data processing,
and have begunn to offer full quantification as exemplified by
the recent introduction of such a SPECT/CT system at the
annual meeting of the EANM in Lyon last year.
Originally, SPECT/CT was not considered a true compet-
itor to radiological imaging procedures. This is in contrast to
PET/CT, which rivalled classical CT and MR imaging in
several indications. Today, the perception of SPECT/CT has
changed. The technology has matured and more data are
available to appraise its clinical role.
In this supplement of the European Journal of Nuclear
Medicine and Nuclear Imaging, we bring together the per-
spectives and opinions of experts in physics, radiology and
nuclear medicine from around the world, which show the vital
potential of clinical routine and research applications in state-
of-the-art SPECT/CT. All contributors are known and
respected experts in their field with a broad clinical and
methodological expertise. The topics in this supplement are
allocated into basic and preclinical sciences, clinical diagnos-
tic topics and special (technical as well as clinical) indications.
In the basic and preclinical section, Hutton discusses the
origins of SPECT/CT, providing a technological and method-
ological overview from the early Anger camera to the first
SPECT/CT prototypes and current state-of-the-art SPECT/CT
systems [5]. As an addition, Bailey et al. provide emerging
evidence that SPECT/CT can be as quantitative as PET/CT
with the application of routine corrections [6]. Moving to the
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tracer side, Gnanasegaran and Ballinger in their comprehen-
sive overview discuss tracers used routinely in SPECT/CT, as
well as new tracers currently under evaluation [7]. New tracer
concepts point to the steady academic interest and further
illustrate the potential for increasing the range of applications
of SPECT/CT. Lastly, Bernsen summarizes current preclinical
applications in small-animal imaging in SPECT combined
with CT and MRI [8].
The next articles in the clinical diagnostic section provide
insights into the use of SPECT/CT in clinical routine cases
scenarios, and they emphasize new fields in which SPECT/CT
is being adopted, perhaps partly against the inclination of
users who prefer MRI. Huellner and Strobel give examples
demonstrating the value of SPEC/CT in imaging of the ex-
tremities, and show that SPECT/CT provides additional and
therapeutically relevant information, such as in the imaging of
hand and feet [9]. While such imaging is mainly in the context
of chronic diseases, Scheyerer et al. also explore the possibil-
ity of integrating SPECT/CT in the subacute setting in trau-
matic diseases [10]. Furthermore, Abikhzer and Keidar sum-
marize vital applications in oncology imaging, despite the
increasing omnipresence of PET/CT in that area [11].
Mortensen and Gutte [12] and Gaemperli et al. [13] review
two distinct procedures: the first explains the interest in pul-
monary embolism imaging that is again increasing, and the
latter points to the possibilities in combined cardiac perfusion/
CTA evaluation. Last but not least in this section, Nadel
provides an intuitive overview on pediatric imaging protocols
and selected experience with SPECT/CT [14].
The third section on special indications provides insights
into the new and upcoming role of SPECT/CT in SIRT pro-
cedures. Brix et al. discuss new data on optimization and dose
adaptionmeasures to meet national diagnostic reference levels
for standard situations [15]. And finally, Beckers and Hustinx
provide an outline of the overarching theme of planning and
conducting combined imaging procedures at the interface of
nuclear medicine and radiology departments [16].
We thank all authors and contributors as well as the re-
viewers for their help with this timely supplement to the
EJNMMI in 2014. Although it remains to be seen to what
extent SPECT/CT may continue to grow in the context of the
overview presented, we may speculate that the advent of
commercially available quantitative methods, in particular,
will place SPECT/CT in a more competitive position among
clinical imaging techniques. Like PET/CT, SPECT/CT offers
true multimodality imaging. By combining function and
anatomy, SPECT/CTwill support state-of-the-art patient man-
agement and foster academic and clinical research interests in
the years to come.
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